Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8829 in Healthy Subjects
NCT07083362Phase 1Completed
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-8829 in ischemic stroke (5 arms), sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Primary endpoint: Incidence and severity of adverse events at Day 21. Started Aug 2025; status: completed.
02
Drugs
HRS-8829
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07083362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083362.